Tradestie Institutional Equity Comparison Engine
DCTH vs RMD โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
RMD Overall Edge
RMD Captures Institutional Edge (3โ1 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to ResMed Inc. (RMD) driven by superior Valuation, Growth & Margin, Options & Structure while DCTH counters with relative strength in Momentum & Technical. Fundamentally, DCTH trades at N/M Forward P/E with 5.2% operating margin (+70.7% YoY revenue) versus RMD at 19.8x Forward P/E and 34.0% operating margin (+5.9% YoY). In options structure, DCTH sits in BREAKOUT (43rd %ile IV; Dealer Gamma Walls on Pro) against RMD sits in CONSOLIDATION (22nd %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
RMD
DCTH N/M vs RMD 19.8x Fwd P/E
Growth & Margin Winner
RMD
Op Margin 5.2% vs 34.0% ยท YoY +70.7% vs +5.9%
Momentum & Technical Winner
DCTH
1Y +128.6% vs -5.1% ยท 52W Pos 80% vs 61%
Options & Structure Winner
RMD
BREAKOUT (43rd %ile IV) vs CONSOLIDATION (22nd %ile IV)
DCTH
NASDAQ
Delcath Systems Inc
Surgical & Medical Instruments & Apparatus
$19.68
-4.23% 1D
Market Cap
$743.8M
1M Return
+39.77%
1Y Return
+128.57%
Forward P/E
N/M
Unified AI Score
35.9 / 100
SELL
Tech 50.0
Fund 38.0
Flow 60.0
Mom 54.0
RMD
NYSE
ResMed Inc.
Surgical & Medical Instruments & Apparatus
$239.34
-0.08% 1D
Market Cap
$33.6B
1M Return
+0.16%
1Y Return
-5.06%
Forward P/E
19.8x
Unified AI Score
59.0 / 100
HOLD
Tech 62.0
Fund 59.0
Flow 68.0
Mom 60.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
DCTH +128.57%
RMD -5.06%
Spread: +133.63 pp (DCTH Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DCTH Revenue | RMD Revenue | DCTH Op. Margin | RMD Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | N/A | $2.61B | N/A | 22.2% | RMD |
| FY2020 | N/A | $2.96B | N/A | 27.4% | RMD |
| FY2021 | $0M | $3.20B | -690.0% | 28.3% | RMD |
| FY2022 | $0M | $3.58B | -1245.1% | 28.0% | RMD |
| FY2023 | $0M | $4.22B | -1849.0% | 26.8% | RMD |
| FY2024 | $40M | $4.69B | -33.4% | 28.2% | RMD |
| FY2025 | $90M | $5.15B | 0.8% | 32.7% | RMD |
| FY2026 | N/A | $5.65B | N/A | 33.4% | RMD |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | DCTH | RMD | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $743.8M | $33.6B | Larger Scale | RMD |
| Trailing P/E Ratio Valuation | 133.6x | 21.8x | Lower Multiple | RMD |
| Forward P/E Ratio Valuation | N/M | 19.8x | Lower Multiple | RMD |
| Revenue Growth (YoY) Growth | +70.7% | +5.9% | Higher Growth | DCTH |
| Operating Margin (TTM) Profitability | 5.2% | 34.0% | Higher Margin | RMD |
| Net Profit Margin Profitability | 6.0% | 27.8% | Higher Margin | RMD |
| Return on Equity (ROE) Capital Efficiency | 5.4% | 26.4% | Higher ROE | RMD |
| 52-Week Range Position Momentum | 80% ($8โ$23) | 61% ($180โ$278) | Stronger Trend | DCTH |
| Beta / 30D Volatility Risk Regime | 1.63ฮฒ ยท 131% Vol | 0.41ฮฒ ยท 43% Vol | Lower Realized Risk | RMD |
| Unified Institutional Score Composite Signal | 35.9 / 100 (SELL) | 59.0 / 100 (HOLD) | Higher Composite | RMD |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full DCTH vs RMD Buy Guide
DCTH
BREAKOUT
66d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
43rd %ile
IV Regime
Balanced (25thโ60th %ile)
RMD
CONSOLIDATION
58d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
22nd %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither DCTH nor RMD registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.